Injection site reactions: Redness, itching, or swelling at the site of injection may occur
Tirzepatide , a dual GIP/GLP-1 receptor agonist, demonstrated superior efficacy to semaglutide in a landmark head-to-head trial, with patients receiving ZEPBOUND losing an average of 50 pounds over 72 weeks compared with 33 pounds among WEGOVY-treated patients
Every time you reconstitute a vial, you should be confident that the solution you create is sterile, accurately concentrated, and biologically active
Your prescription is shipped to your home
It is not indicated for the treatment of generalized arteriosclerosis associated with advancing age
These options are listed for information only your own clinician decides what is appropriate for you